Brexit spurs SPC litigation doubt for pharma companies
Pharma businesses say they are uncertain of whether decisions around Article 3a of the EU’s SPC Regulation would be followed in the UK for very long after Brexit – and that divergence might further complicate their litigation strategies.
Open source licence risks drive better governance to protect patents
Ericsson, Benevolent AI and a bank say that open-source software is a valuable resource for driving innovation, but that businesses using it must have the right controls to ensure that they don’t carelessly take a restrictive licence that renders their patent estates worthless.
Sign up to receive more content like this in Patent Strategy’s weekly newsletter.
